The burgeoning landscape of emerging treatments for metabolic management has seen the rise of both retatrutide and tirzepatide, both dual mechanism agonists targeting the GLP-1 and GIP receptors. While sharing a https://nellwhge386014.wikissl.com/1948852/retatrutide_vs_tirzepatide_a_comparative_analysis